Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration
Plasma biomarkers for Alzheimer's disease (AD) were assessed in a real-world memory clinic population. Kidney dysfunction and cardiovascular risk factors influenced plasma biomarker levels. Phosphorylated tau (p-tau)217 and p-tau217/amyloid beta (Aβ)42 ratio showed strongest association with AD pathology. Aβ42/40 ratio's accuracy was improved by including comorbidities into the diagnostic algorithms.
Authors
- Nicholas James Ashton (ORCID: https://orcid.org/0000-0002-3579-8804)
- Anna Matton (ORCID: https://orcid.org/0000-0002-7819-0495)
- Makrina Daniilidou (ORCID: https://orcid.org/0000-0002-5460-9802)
- Kaj Blennow (ORCID: https://orcid.org/0000-0002-1890-4193)
- Göran Hagman (ORCID: https://orcid.org/0000-0003-0238-8646)
- Anna Rosenberg (ORCID: https://orcid.org/0000-0003-1456-7991)
- Ulf Öhlund‐Wistbacka
- Henrik Zetterberg (ORCID: https://orcid.org/0000-0003-3930-4354)
- Miia Kivipelto (ORCID: https://orcid.org/0009-0001-1069-1787)
Institutions
- Public Health Agency of Sweden (SE)
- Karolinska University Hospital (SE)
- University of Eastern Finland (FI)
- Sahlgrenska University Hospital (SE)
- Charing Cross Hospital (GB)
- Karolinska Institutet (SE)
- Finnish Institute for Health and Welfare (FI)
- UK Dementia Research Institute (GB)
- University College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz.70931
- Citations
- 2
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Gun och Bertil Stohnes Stiftelse
- Stiftelsen för Gamla Tjänarinnor
- Karolinska Institutet
- Vetenskapsrådet
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- Alzheimerfonden
- Center for Innovative Medicine